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Objectives The purpose of this study was to investigate the evolution of patient selection criteria for transcatheter aortic
valve implantation (TAVI) and its impact on clinical outcomes.
Background Anecdotal evidence suggests that patient selection for TAVI is shifting toward lower surgical risk patients. The
extent of this shift and its impact on clinical outcomes, however, are currently unknown.
Methods We conducted a single-center study that subcategorized TAVI patients into quartiles (Q1 to Q4) defined by enroll-
ment date. These subgroups were subsequently examined for differences in baseline characteristics and 30-day
and 6-month mortality rate. The relationship between quartiles and mortality rate was examined using unad-
justed and adjusted (for baseline characteristics) Cox proportional hazard models.
Results Each quartile included 105 patients (n  420). Compared with Q4 patients, Q1 patients had higher logistic Euro-
SCORES (25.4  16.1% vs. 17.8  12.0%, p  0.001), higher Society of Thoracic Surgeons scores (7.1  5.5%
vs. 4.8  2.6%, p  0.001), and higher median N-terminal pro–B-type natriuretic peptide levels (3,495 vs. 1,730
ng/dl, p  0.046). From Q1 to Q4, the crude 30-day and 6-month mortality rate decreased significantly from
11.4% to 3.8% (unadjusted hazard ratio [HR]: 0.33; 95% confidence interval [CI]: 0.11 to 1.01; p  0.053) and
from 23.5% to 12.4% (unadjusted HR: 0.49; 95 CI: 0.25 to 0.95; p  0.07), respectively. After adjustment for
baseline characteristics, there were no significant differences between Q1 and Q4 in 30-day mortality rate (ad-
justed HR ratio: 0.29; 95% CI: 0.08 to 1.08; p  0.07) and 6-month mortality rate (HR: 0.67; 95% CI: 0.25 to
1.77; p  0.42).
Conclusions The results of this study demonstrate an important paradigm shift toward the selection of lower surgical risk
patients for TAVI. Significantly better clinical outcomes can be expected in lower than in higher surgical risk pa-
tients undergoing TAVI. (J Am Coll Cardiol 2012;59:280–7) © 2012 by the American College of Cardiology
Foundation
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accepted October 17, 2011.with severe aortic stenosis. Similar to coronary stent use for
off-label indications (1–6), there is some evidence to suggest
that patient selection criteria for transcatheter aortic valve
implantation (TAVI) are evolving away from the pre-
market inclusion and exclusion criteria (7). This could mean
that transcatheter aortic valves are implanted in higher or
lower risk patients than those originally included in the
initial safety and feasibility trials. Anecdotally, the paradigm
shift appears to be in the direction of treating less sick
patients with TAVI. The extent of this shift and its impact
on clinical outcomes, however, are still uncertain. The
Medtronic CoreValve SURTAVI (Surgical Replacement
and Transcatheter Aortic Valve Implantation) trial and Ed-
wards PARTNER 2 (Placement of AoRTic TraNscathetER
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stages of development, will be concerned with randomizing
intermediate to high surgical risk patients to TAVI or
surgical aortic valve replacement. These trials provide us
with yet another indication that TAVI is being directed at
the treatment of lower and lower surgical risk patients.
To investigate the evolution of patient selection criteria
for TAVI , we conducted a single-center study that subcat-
egorized a total of 420 TAVI patients into quartiles and
subsequently examined the temporal changes in baseline
characteristics and the impact of TAVI on survival.
Methods
Patient selection. Between June 2007 and June 2010, 420
patients underwent TAVI at the German Heart Center
Munich. High surgical risk patients with severe aortic valve
stenosis were referred for TAVI after a dedicated team of
cardiac surgeons, cardiologists, and anesthesiologists
reached a consensus that TAVI was in the best interest of
these patients. Informed consent was subsequently obtained
from all patients.
Suitability for TAVI was confirmed by a combination of
imaging modalities: transesophageal echocardiography,
multislice computed tomography, and angiography. Our
approach to prosthesis type (Medtronic CoreValve or Ed-
wards SAPIEN) and size selection and vascular access route
was described in detail elsewhere (8). Briefly, patients were
considered for TAVI if the aortic valve annulus diameter
was 18 to 27 mm. Our strategy for vascular access is based
on minimal invasiveness. Thus, we first consider a trans-
femoral CoreValve approach, followed by subclavian CoreValve,
and finally transapical Edwards SAPIEN.
Device description and procedure. Details of the Medtronic
CoreValve and Edwards SAPIEN device, and technical
aspects of the procedure, were previously published (8).
Procedures were performed in a hybrid surgical suite.
Depending on underlying comorbidities, patients received
either general or local (with mild sedation) anesthesia. With
increasing experience, there was a conscious decision to use
local anesthesia, especially during transfemoral valve im-
plantations. Transfemoral vascular access was obtained ei-
ther percutaneously (pre-closed with a 10-F Prostar XL and
a 6-F Perclose ProGlide, Abbott Vascular, Abbott Park,
Illinois) or by surgical cutdown.
Post-implantation dilation or a second transcatheter valve
may have been required in cases of significant paravalvular
aortic regurgitation.
Definition of outcomes. The primary endpoint is all-cause
mortality rate at 30-day and 6-month follow-up. To ensure
adequate 6-month follow-up, the enrollment period ended
on June 31, 2010. Secondary endpoints included stroke/
transient ischemic attack, vascular complications requiring
any percutaneous or surgical correction, and need for a new
permanent pacemaker within 14 days of the procedure.
Post-implantation aortic regurgitation estimated by echo- 0cardiography was categorized as
none/trivial (0 to 1), mild (2), or
moderate/severe (3 to 4).
Statistical analyses. The 420 pa-
tients were subdivided into equal
quartiles (each quartile with 105
patients). The 4 subgroups were
subsequently analyzed for differ-
ences in baseline characteristics
and clinical outcomes.
Continuous variables were tested
for normality using the Shapiro-
Wilks goodness-of-fit test; normally distributed variables
are presented as mean  SD and non-normally distributed
variables are presented as median (interquartile range).
Dichotomous or nominal variables are described as numbers
and percentages.
One-way analysis-of-variance was used to compare means
across quartiles; post hoc pairwise comparison was done with
Bonferroni correction. In cases of nonparametric distribution
or ordinal data, the Kruskal-Wallis analysis of ranks was used;
post hoc comparison was done using the Mann-Whitney test
(Wilcoxon rank sum test) with Bonferroni correction. Cate-
gorical variables were compared by the Pearson chi-square test
or, when indicated, the Fisher exact test.
A Cox proportional hazard regression model provided
event rate graphs for 30-day and 6-month mortality rate for
quartiles 1 to 4. Two models were used: an unadjusted
model and an adjusted model that included baseline char-
acteristics associated with mortality rate in a univariable
analysis. Because of its skewed distribution, the natural
logarithm of pro–B-type natriuretic peptide was used in the
Cox regression models. Although a p value 0.10 was used
for the inclusion of covariates into the univariable model, a
p value 0.05 was used as the criterion for statistical
significance in the multivariable model.
All statistical analyses were performed using SPSS ver-
sion 17.0 (SPSS Inc., Chicago, Illinois). Unless otherwise
specified, a 2-tailed p value of 0.05 was considered
statistically significant.
Results
Baseline and procedural characteristics. The overall and
quartile (Q)-based patient demographics and procedural
characteristics are summarized in Tables 1 and 2,
respectively.
Patients undergoing TAVI in the first quartile had
significantly higher logistic EuroSCORES than those in the
second, third, or fourth quartiles (Q1: 25.4  16% vs. Q2:
18.8  10% vs. Q3: 18.3  11% vs. Q4: 17.8  12%,
nalysis of variance p  0.001). The Society of Thoracic
urgeons (STS) score was significantly lower in Q4 than in
1, Q2, or Q3 (Q1: 7.1 5.4% vs. Q2: 6.2 3.5% vs. Q3:
.8  3.9% vs. Q4: 4.8  2.6%, analysis of variance p 
Abbreviations
and Acronyms
CI  confidence interval
HR  hazard ratio
SAVR  surgical aortic
valve replacement
STS  Society of Thoracic
Surgeons
TAVI  transcatheter aortic
valve implantation.001).
sease;
p Predicte
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decreased from 87 (13%) in Q1 to 59 (41%) in Q4 (p 
0.001). Correspondingly, the number of transfemoral cases
decreased by 36% from Q1 to Q4 (85% vs. 49%, p 0.001).
There was a 30% reduction in the use of general anesthesia over
time (Q1: 100% vs. Q4: 69%, p  0.001) and less contrast was
used in Q4 than in Q1 (156 69 ml vs. 104 41 ml, p 0.001).
Baseline Characteristics for the Overall Cohort and Quartiles 1 to 4Table 1 Baseline Characteristics for the Overall Cohort and Qu
Overall Cohort Q1
Age, yrs 80.3 7.1 81.11 7.00
Female 265 (63) 58 (55.2)
Logistic EuroSCORE, % 20.17 13.00 25.44 16.0
STS-PROM, % 6.1 4.1 7.13 5.4
NYHA functional class III or IV 406 (96.7) 104 (99)
CAD 230 (55) 52 (49.5)
Left ventricular ejection fraction
50% 262 (62.4) 60 (57.1)
35%–50% 93 (22.1) 22 (21)
35% 65 (15.5) 23 (21.9)
Atrial fibrillation 97 (23.3) 26 (24.8)
Stroke 55 (13.2) 8 (7.6)
PAD 99 (23.7) 29 (27.6)
Creatinine, mg/dl 1.20 0.56 1.24 0.58
Pulmonary disease 85 (20.3) 28 (26.7)
Pulmonary hypertension 96 (23.3) 28 (26.7)
Previous cardiac surgery
CABG surgery 49 (11.7) 13 (12.4)
Aortic valve surgery 6 (1.4) 0 (0)
Atrioventricular valves 9 (2.2) 1 (1)
Combination 13 (3.1) 2 (1.9)
Pro-BNP levels, ng/l 2,680 (1,173–6,337) 3,495 (1,395–7,162)
Values are mean SD, n (%), or median (interquartile range). *Significant difference between Q1 and
BNP B-type natriuretic peptide; CABG coronary artery bypass graft; CAD coronary artery di
ro-BNP  pro–B-type natriuretic peptide; Q  quartile; STS PROM Society of Thoracic Surgery
Procedural Characteristics of Overall Cohort and Quartiles 1 to 4Table 2 Procedural Characteristics of Overall Cohort and Quart
Overall Cohort Q1
Valve type
Medtronic CoreValve 285 (68.7) 91 (86.7)
Edwards SAPIEN 127 (30.6) 14 (13.3)
Access (intention to treat)
Transfemoral 256 (61) 89 (84.8)
Transaxillary 28 (6.7) 3 (2.9)
Transapical 130 (31) 13 (12.4)
Transaortic 6 (1.4) 0 (0)
Intubation, no. (%) 358 (85.6) 105 (100.0)
Contrast use, ml 125 56 156 69
Valve-in-valve implantation 11 (2.6) 4 (3.8)
Post-implantation dilation 68 (16.6) 23 (21.9)
Pericardial effusion 1 cm 14 (3.3) 3 (2.9)
Post-implantation AR
0–1 351 (84.6) 92 (87.6)
2 only 38 (9.2) 8 (7.6)
3–4 26 (6.3) 5 (4.8)
Values are n (%) or mean SD. *Statistically significant between Q1 and Q2, Q1 and Q3, and Q1 an
between Q1 and Q3, Q1 and Q4, Q2 and Q3, and Q2 and Q4. §Statistically significant between e
Q1 and Q3, Q1 and Q4, and Q2 and. Q3.
AR  aortic regurgitation; Q  quartile.Association of baseline characteristics with 30-day and
6-month mortality rate. Univariable analysis revealed that
age, logistic STS score, atrial fibrillation, previous cardiac
surgery, and previous stroke were associated with 30-day
mortality rate (p  0.10) (Table 3).
Univariable analysis revealed that age, logistic EuroSCORE,
STS score, left ventricular ejection fraction, atrial fibrillation,
s 1 to 4
Q2 Q3 Q4 p Value
81.1 7.2 80.19 6.20 78.9 7.9 0.09
63 (60) 76 (72.4) 68 (64.8) 0.065
18.9 10.0 18.3 11.0 17.8 12.0 0.001*
6.2 3.5 5.8 3.9 4.8 2.6 0.001†
99 (94.3) 101 (96.2) 102 (97.2) 0.27
58 (55.2) 56 (53.8) 64 (61.5) 0.37
0.065
66 (62.9) 62 (59) 74 (70.5)
21 (20) 32 (30.5) 18 (17.1)
18 (17.1) 11 (10.1) 13 (12.4)
21 (20) 26 (25.2) 24 (22.9) 0.80
14 (13.3) 19 (18.4) 14 (13.6) 0.14
31 (29.5) 19 (18.3) 20 (19.4) 0.13
1.28 0.59 1.17 0.50 1.10 0.56 0.015
21 (20) 19 (18.3) 17 (16.3) 0.27
23 (21.9) 20 (19.2) 25 (25.5) 0.57
0.097
19 (18.1) 6 (5.8) 11 (10.6)
0 (0) 2 (1.9) 4 (3.8)
2 (1.9) 4 (3.8) 2 (1.9)
3 (2.9) 3 (2.9) 5 (4.8)
850 (1,050–8,010) 2,290 (1,190–5,310) 1,730 (746–4,435) 0.082
, Q4. †Significant difference between Q4 and Q1, Q2, Q3. ‡Significant difference between Q1 and Q4.
IQR interquartile range; NYHA New York Heart Association; PAD peripheral arterial disease;
d Risk of Mortality.
to 4
Q2 Q3 Q4 p Value
0.001*
1 (68.3) 63 (60.0) 60 (59.4)
3 (31.7) 42 (40.0) 41 (40.6)
0.001†
5 (61.9) 51 (48.6) 51 (48.6)
1 (1.0) 10 (9.5) 14 (13.3)
5 (33.3) 42 (40) 40 (38.1)
4 (3.8) 2 (1.9) 0 (0)
5 (100.0) 76 (73.1) 72 (69.2) 0.001‡
8 54 110 42 104 41 0.001§
5 (4.8) 1 (1.0) 1 (1.0) 0.25
4 (13.5) 19 (18.3) 12 (12.4) 0.22
3 (2.9) 6 (5.7) 2 (1.9) 0.44
0.5
7 (84.5) 83 (81.3) 89 (84.8)
9 (8.7) 10 (9.8) 11 (10.5)
7 (6.8) 9 (8.8) 5 (4.8)
Statistically significant between each quartile except between Q3 and Q4. ‡Statistically significant
rtile except between Q2 and Q3 and Q3 and Q4. Statistically significant between Q1 and Q2,artile
2,
Q2, Q3iles 1
7
3
6
3
10
12
1
8
d Q4. †
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and N-terminal pro–B-type natriuretic peptide (p  0.10) were
associated with 6-month mortality rate (Table 4).
The crude and adjusted hazard ratios (HRs) for 30-day
and 6-month mortality rate are shown in Tables 5 and 6.
From Q1 to Q4, the crude 30-day mortality rate signif-
icantly decreased from 11.4% to 3.8% (chi-square test, p 
0.03) (unadjusted HR: 0.33; 95% confidence interval [CI]:
0.11 to 1.01; p  0.051) and the 6-month mortality rate
significantly decreased from 23.5% to 12.4% (chi-square
test, p  0.031) (unadjusted HR: 0.49; 95% CI: 0.25 to
0.95; p  0.072) (Fig. 1A). There were no significant
differences in mortality rate observed between Q1 and Q4
after adjustment for baseline characteristics at 30-day and
6-month follow-up (30-day mortality rate adjusted HR:
0.29; 95% CI: 0.08 to 1.08; p  0.07) (6-month adjusted
mortality rate HR: 0.67; 95% CI: 0.25 to 1.77; p  0.42)
(Fig. 1B).
There were no significant differences in 30-day and
6-month mortality rates in patients undergoing transfemo-
ral TAVI and transapical TAVI (30-day HR: 1.07; 95% CI:
0.54 to 2.11; p  0.83) (6-month HR: 1.13; 95% CI: 0.71
to 1.80; p  0.60). Similar findings were noted within
quartiles.
Secondary clinical endpoints. Clinical outcomes at 30
days and 6 months are shown in Table 7. Transfemoral
vascular complications decreased by 17% from Q1
Univariable Analysis for Predictorsof 30-Day Mortality RateTable 3 Univariable Analysis for Predictorsof 30-Day Mortality Rate
Hazard Ratio 95% CI p Value
Age, yrs 1.01 1.04–1.17 0.001
Female 0.72 0.36–1.42 0.34
Logistic EuroSCORE, % 1.01 0.90–1.03 0.33
STS-PROM, % 1.06 1.002–1.12 0.043
NYHA functional class III or IV 0.66 0.16–2.70 0.57
Coronary artery disease 1.05 0.56–1.98 0.86
Ejection fraction 0.50
50% Reference
35%–50% 1.57 0.54–4.50 0.40
35% 1.90 0.62–6.16 0.24
Atrial fibrillation 0.56 0.23–1.35 0.20
Stroke/transient ischemic attack 3.06 1.20–7.80 0.019
Peripheral arterial disease 1.28 0.64–2.50 0.47
Creatinine, mg/dl 1.25 0.79–1.99 0.33
Pulmonary disease 1.34 0.65–2.71 0.41
Pulmonary hypertension 1.00 0.47–2.12 0.99
Previous cardiac surgery 0.22
None Reference
CABG surgery 1.32 0.18–9.62 0.78
Atrioventricular valves 0.52 0.05–5.83 0.6
Aortic valve surgery 0.01 0.00–0.01 0.97
Combination 5.40 0.49–60.4 0.16
Log NT-proBNP 1.26 0.62–2.56 0.5
CI  confidence interval; Log NT-proBNP  log N-terminal pro–B-type natriuretic peptide; other
bbreviations as in Table 1.(26.9%) to Q4 (9.5%) (p  0.008). Although the absolutepercentages trended downward, there were no significant
differences observed in the rate of stroke/transient isch-
emic attack or need for a permanent pacemaker from Q1
to Q4.
Discussion
In the present study, we found that the crude 30-day and
6-month mortality rates improved from Q1 to Q4. Al-
though no significant differences in mortality were observed
between Q1 and Q4 after adjustment for baseline charac-
teristics, an important signal between quartiles remained.
With growing experience, we observed a shift toward the
treatment of younger patients with fewer comorbidities and
lower surgical risk scores (logistic EuroSCORE and STS
score). The results of this study suggest that improved
survival outcomes can be expected in lower surgical risk
patients undergoing TAVI.
Possible explanations for the progressive decrease in mortal-
ity observed in the present study include patient-, operator/
procedure-, and device-related factors. Although we would
expect improved outcomes in treating less complex patients
with TAVI, this has not been previously demonstrated. From
Q1 to Q4, we observed a significant mortality reduction at
both 30-day (11.4% to 3.8%) and 6-month (23.5% to 12.4%)
follow-up. After adjusting for baseline characteristics (patient-
related factors), however, there were no statistically significant
differences in 30-day or 6-month mortality among quartiles.
These results suggest that underlying comorbidities play an
Univariable Analysis for Predictorsof 6-Month Mortality RateTable 4 Univ riable Analysis for Predictorsof 6-Month Mortality Rate
Hazard Ratio 95% CI p Value
Age, yrs 1.02 0.98–1.05 0.20
Female 0.96 0.61–1.49 0.86
Logistic EuroSCORE, % 1.01 0.99–1.02 0.11
STS-PROM, % 1.09 1.03–1.12 0.001
NYHA functional class III or IV 0.93 0.29–2.96 0.90
CAD 0.86 0.56–1.32 0.49
Ejection fraction, % 0.04
50 Reference
35–50 0.93 0.50–1.70 0.82
35 0.55 0.32–0.96 0.04
Atrial fibrillation 1.46 0.92–2.33 0.10
Stroke/TIA 3.41 1.70–6.70 0.001
PAD 1.56 0.98–2.40 0.06
Creatinine, mg/dl 1.33 0.98–1.79 0.06
Pulmonary disease 1.56 0.96–2.50 0.06
Pulmonary hypertension 1.08 0.65–1.80 0.74
Previous cardiac surgery 0.32
None Reference
CABG surgery 1.17 0.25–5.40 0.83
Atrioventricular valves 0.10 0.01–0.30 0.96
Aortic valve surgery 3.29 1.03–10.51 0.04
Combination 0.73 0.18–2.99 0.66
Log NT-proBNP 1.64 1.04–2.58 0.03TIA  transient ischemic attack; other abbreviations as in Tables 1 and 3.
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TAVI and Lower Surgical Risk Patients January 17, 2012:280–7important role in acute and intermediate-term survival after
TAVI. These findings do not exclude the potential contribu-
tion of a learning curve, changes in procedural techniques, or
device improvements. Notwithstanding their importance,
these latter factors were not included in the present analysis
because the information was not collected or it was difficult to
quantify/record such phenomena.
Previous publications have alluded to an improvement in
outcomes with growing experience (9–11). Without con-
trolling for confounding, these reports suggested that a
learning curve (operator experience) and device iterations
accounted for the reduction in adverse events over time.
Nonetheless, the authors did not provide adjusted mortality
figures to investigate the possible contribution of changing
baseline characteristics over time.
The baseline characteristics observed in Q1 (e.g., mean
age 81 years; STS score 7%) are suggestive of those found in
contemporary TAVI studies (9–17). In contrast, and to our
knowledge, patient characteristics similar to those in Q4
(e.g., mean age 78 years; STS score, 4%) have not been
previously reported in a TAVI-related study. This change in
patient selection pattern is likely fueled by increasing oper-
ator/team experience and improving clinical outcomes. At
our center, patient selection is performed by a team of
cardiac surgeons, cardiologists, and anesthesiologists. Fur-
thermore, clinical judgment, as opposed to any surgical risk
algorithm, plays a fundamental role in the selection of
patients for TAVI.
Recent TAVI publications report a 30-day mortality rate
Unadjusted and Adjusted Hazard Ratiofor 30-Day Mortality Rate Across QuartilesTable 5 Unadjusted and Adjusted Hazard Ratiofor 30-Day Mortality Rate Across Quartiles
Hazard Ratio 95% CI p Value
Unadjusted 30-day mortality rate
Quartiles 0.21
1 Reference
2 0.99 0.45–2.21 0.99
3 0.99 0.45–2.21 0.98
4 0.32 0.10–1.00 0.051
Adjusted 30-day mortality rate
Age, yrs 1.09 1.02–1.17 0.006
STS-PROM, % 1.01 0.94–1.08 0.85
Atrial fibrillation 0.63 0.26–1.52 0.30
Stroke 0.92 0.32–2.65 0.88
Previous cardiac surgery 0.061
None Reference
CABG surgery 0.45 0.11–1.90 0.27
Atrioventricular valves 0.00 0.00–0.00 0.97
Aortic valve surgery 9.53 1.90–47.68 0.005
Combination 1.78 0.23–13.59 0.58
Quartiles 0.24
1 Reference
2 0.96 0.42–2.20 0.93
3 1.01 0.44–2.32 0.98
4 0.31 0.09–1.08 0.071
Abbreviations as in Tables 1 and 3.ranging from 6.7% to 13% (13–18). Our overall 30-daymortality rate of 9.5% is well within this range. However, in
our last 105 patients with a mean age of 78 years, an STS
score of 4.6%, a and logistic EuroSCORE of 17.8%, the
30-day mortality was 3.8%. Keeping this in mind, Grossi et
al. (19) reported a 30-day mortality of 7.8% after surgical
aortic valve replacement in a cohort of 731 high-risk
patients with a mean logistic EuroSCORE of 17.2%. In
that study, 43% were seputagenarians and 44% were octo-
genarians or nonagenarians.
The Bern-Rotterdam collaboration recently published a
propensity score-matched analysis comparing TAVI and
surgical aortic valve replacement (SAVR) (20). Compared
with the unmatched TAVI cohort, the matched TAVI
cohort were younger (mean age 79 vs. 84 years, p  0.001),
had lower logistic EuroSCORES (16% vs. 22%, p 0.001),
ad less severe symptoms, and were less likely to report a
istory of coronary artery bypass surgery, atrial fibrillation,
troke, peripheral vascular disease, or pulmonary hyperten-
ion. Based on pre-specified methods to control for con-
ounding, the authors concluded that 30-day survival rates
ay be similar among selected TAVI and SAVR patients.
he authors considered that the matched TAVI cohort
Unadjusted and Adjusted Hazard Ratiofor 6-Month Mortality Rate Across QuartilesTable 6 Unadjusted and Adju ted Hazard Ratiofor 6-Month Mortality Rate Across Quartiles
Hazard Ratio 95% CI p Value
Unadjusted hazard ratio
Quartiles 0.18
1 Reference
2 0.89 0.50–1.56 0.68
3 0.89 0.51–1.57 0.69
4 0.48 0.24–0.94 0.03
Adjusted hazard ratio
Age, yrs 1.01 0.97–1.06 0.54
Logistic EuroSCORE, % 0.98 0.95–1.01 0.19
STS-PROM, % 1.08 1.00–1.15 0.04
Log NT-proBNP 1.07 0.55–2.06 0.84
Atrial fibrillation 1.58 0.88–2.58 0.12
Ejection fraction, no. (%) 0.025
50% Reference
35%–50% 2.30 1.21–4.50 0.011
35% 2.11 0.99–4.50 0.051
Previous cardiac surgery 0.93
None Reference 0.83
CABG surgery 1.11 0.45–2.76 0.97
Atrioventricular valves 0.00 0.00–0.00 0.97
Aortic valve surgery 0.00 0.00–0.00 0.98
Combination 2.16 0.41–11.29 0.36
Creatinine, mg/dl 0.84 0.48–1.46 0.53
COPD 1.64 0.89–3.03 0.11
Stroke 1.37 0.65–2.89 0.41
Quartiles 0.61
1 Reference
2 0.89 0.45–1.76 0.74
3 0.82 0.40–1.68 0.59
4 0.54 0.22–1.34 0.19COPD  chronic obstructive pulmonary disease; other abbreviations as in Table 3.
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January 17, 2012:280–7 TAVI and Lower Surgical Risk PatientsFigure 1 Unadjusted and Adjusted Cox Proportional Hazards Model for All-Cause Mortality Rate Through 6-Month Follow-Up
(A) Significant differences in the 30-day and 6-month crude hazard ratios for all-cause mortality rate between the fourth quartile of enrollment and the first, second, and
third quartiles. (B) After adjusting for baseline characteristics, there were no statistically significant differences in 30-day and 6-month hazard ratios among quartiles.
This suggests that baseline characteristics play a role in the clinical outcomes of transcatheter aortic valve implantation patients at 30-days and 6-month follow-up.
These results do not exclude the possibility of a technical learning curve or improvements in device iterations as additional explanations for the observed differences in
mortality among quartiles. CI  confidence interval; HR  hazard ratio; Q  quartile.
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TAVI and Lower Surgical Risk Patients January 17, 2012:280–7could be eligible for a randomized comparison of TAVI and
SAVR. It is likely that future randomized trials comparing
AVI and SAVR (e.g., SURTAVI and PARTNER 2) will
enroll patients with baseline characteristics similar to
those of the matched TAVI cohort from the Bern-
Rotterdam study and the Q4 cohort in the present study.
We observed an important reduction in the rate of femoral
complications over time. Likely explanations for this include a
learning curve associated with the use of pre-closure devices
and establishing a lower threshold to use subclavian or
transapical access in the setting of aortoiliac disease (calcifica-
tion, tortuosity, or borderline vessel size). Table 2 demonstrates
hat the number of nontransfemoral TAVI cases increased
rom Q1 to Q4. Thus, vascular access site selection is based
ltimately on patient safety; a femoral access route may be
easible in many patients, but a safer access route may exist.
urthermore, in patients with some degree of femoral vessel
alcification undergoing transfemoral TAVI, we prefer to
erform a surgical cutdown. This avoids potential failure of the
re-closure devices and allows the operator to puncture an area
f the vessel devoid of calcification. During our initial experi-
nce, pre-closure was performed using a single 10-F Prostar
evice. Later in our experience, we implemented a double
re-closure technique using a 10-F Prostar device and a 6-F
roglide. The 6-F Proglide provides additional closure in cases
n which the 10-F Prostar fails. Other centers have reported
sing 2 or 3 6-F Proglide devices for pre-closure (21). The
mportant point is that centers are accustomed to an effective,
afe, and reproducible strategy.
tudy limitations. As with any multivariable analysis, the
resent study can be limited by unmeasured confounding.
ecause we only included baseline characteristics in our
odel, it is possible that procedure-, operator-, and device-
elated factors also have an influence on 30-day and
-month mortality. Our goal was to investigate changing
atient selection patterns and its influence on mortality.
onclusions
he results of this study demonstrate an important para-
igm shift toward the selection of lower surgical risk
atients for TAVI. Significantly better clinical outcomes can
e expected in lower than in higher surgical risk patients
ndergoing TAVI. As TAVI becomes more routine and
Clinical OutcomesTable 7 Clinical Outcomes
Overall Cohort
30-day mortality 40 (9.5)
6-month mortality 84 (20)
Stroke/transient ischemic attack 19 (4.5)
Vascular complications (total) 78 (18.8)
Vascular complications (femoral access patients) 67 (16)
Need for permanent pacemaker 88 (21.3)
Values are n (%). *Statistically significant between quartile (Q)1 vs. Q4, Q2 vs. Q4, and Q3 vs. Q4
§statistically significant between Q1 vs. Q4 and Q1 vs. Q3; ¶statistically significant between Q1 videly available, operators may be tempted to implant thedevice in younger patients with less comorbidities. Uncer-
tainties about the long-term durability, in addition to the
unresolved issues of paravalvular aortic regurgitation and
conduction abnormalities, should be cautiously weighed
against the immediate benefits being widely reported.
Reprint requests and correspondence: Dr. Nicolo Piazza, Ger-
man Heart Center, Lazarette Strasse 36, 80636 Munich, Ger-
many. E-mail: nicolopiazza@mac.com.
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